All In MedTech

Device Trial Radar · NCT04708782

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 598 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

598

Actual

Start

Apr 21, 2021

Primary completion

Feb 2, 2026

Study completion Feb 2, 2026

Sponsor

Lead sponsor
United TherapeuticsNot on our public-company list
Sponsor type
Industry
First posted
Jan 14, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.

Conditions

  • Idiopathic Pulmonary Fibrosis
  • Interstitial Lung Disease

Interventions

  • PlaceboDrug

    Placebo administered QID

  • Inhaled TreprostinilDrug

    Inhaled treprostinil (6 mcg/breath) administered QID

  • Treprostinil Ultrasonic NebulizerDevice

    Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Absolute FVC From Baseline to Week 52Time frame: Baseline to Week 52

Locations

96 sites in 2 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama

95 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.